GRAIL (GRAL) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
18 Jun, 2026Opening remarks and agenda
Meeting commenced at 1:00 P.M. PDT on June 18, 2026, with formal business following the agenda and proxy statement.
Introduction of board members, executive officers, and the independent auditor present.
Rules of conduct and voting procedures were outlined for participating stockholders.
Board and executive committee updates
Sarah Krevans and Steve Mizell were nominated for election as Class II directors for a term expiring at the 2029 annual meeting.
Shareholder proposals
Two proposals were presented: election of directors and ratification of the independent auditor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from GRAIL
- Significant growth, clinical validation, and regulatory milestones position the test for broader adoption.GRAL
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 revenue rose 26% to $44.7M, Galleri test volume up 35%, net loss improved 3%.GRALQ2 2026
- RCT data show major stage shift and reduced ER visits, supporting broad adoption and coverage.GRALGoldman Sachs 47th Annual Global Healthcare Conference 2026
- Early-stage cancer detection advances and robust growth position for broader adoption post-FDA review.GRALJefferies Global Healthcare Conference 2026
- MCED testing quadrupled early cancer detection and cut late-stage diagnoses by over 20%.GRALStudy result
- Q3 revenue up 38% YoY, Galleri sales surged 52%, restructuring extends cash runway to 2028.GRALQ3 2024
- Q2 revenue up 43% year-over-year; $1.42B impairment drives $1.59B net loss and restructuring.GRALQ2 2024
- Q1 revenue up 19%, net loss halved, and Galleri test growth supported by positive trial data.GRALQ1 2025
- Revenue up 45% in 2024, TRICARE and Quest expand access, cash runway to 2028.GRALQ4 2024